PMID: 15226675Jul 1, 2004Paper

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

Pharmacogenetics
Mikko NiemiKari T Kivistö

Abstract

This study aimed to characterize possible relationships between polymorphisms in the drug transporter genes organic anion transporting polypeptide-C (OATP-C, SLCO1B1), OATP-B (SLCO2B1), multidrug resistance-associated protein 2 (MRP2, ABCC2) and multidrug resistance transporter (MDR1, ABCB1) and the pharmacokinetics of pravastatin. We studied 41 healthy Caucasian volunteers who had previously participated in pharmacokinetic studies with pravastatin. Six volunteers had a very high pravastatin AUC value and were defined as outliers according to statistical criteria. The OATP-C gene was sequenced completely in all subjects, and they were also genotyped for selected single nucleotide polymorphisms (SNP) in the OATP-B, MDR1 and MRP2 genes. Of the six outliers, five were heterozygous for the OATP-C 521T>C (Val174Ala) SNP (allele frequency 42%) and three were heterozygous for a new SNP in the promoter region of OATP-C (-11187G>A, allele frequency 25%). Among the remaining 35 subjects, two were homozygous and six were heterozygous carriers of the 521T>C SNP (allele frequency 14%, P = 0.0384 versus outliers) and three were heterozygous carriers of the -11187G>A SNP (allele frequency 4%, P = 0.0380 versus outliers). In subjects with the ...Continue Reading

References

Feb 1, 1990·British Journal of Clinical Pharmacology·S M SinghviD A Willard
Feb 1, 1995·Journal of Clinical Pharmacology·J TriscariH Y Pan
May 1, 1994·Clinical Pharmacology and Therapeutics·K T OlkkolaP J Neuvonen
Apr 29, 1998·Clinical Pharmacology and Therapeutics·P J NeuvonenK T Kivistö
Apr 23, 1999·Pharmaceutical Research·R B KimG R Wilkinson
Aug 25, 1999·Clinical Pharmacology and Therapeutics·J J LiljaP J Neuvonen
Aug 22, 2000·European Journal of Clinical Pharmacology·T KantolaP J Neuvonen
Mar 20, 2001·American Journal of Human Genetics·M StephensP Donnelly
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·H G XieC M Stein
Aug 15, 2001·Lancet·E SchaeffelerM Schwab
Aug 15, 2001·Clinical Pharmacology and Therapeutics·R B KimG R Wilkinson
May 31, 2002·Clinical Pharmacokinetics·David Williams, John Feely
Jun 18, 2002·Molecular Pharmacology·Chava Kimchi-SarfatyMichael M Gottesman
Oct 3, 2002·Annual Review of Pharmacology and Toxicology·Matthias SchwabMartin F Fromm
Nov 12, 2002·Clinical Pharmacology and Therapeutics·Andreas JohneIvar Roots
Dec 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Rommel G TironaRichard B Kim
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Yoshihisa ShitaraYuichi Sugiyama
Apr 2, 2003·Pharmacogenetics·Christiane Pauli-Magnus, Peter J Meier
Apr 4, 2003·JAMA : the Journal of the American Medical Association·Paul D ThompsonRichard H Karas
May 2, 2003·The Journal of Pharmacology and Experimental Therapeutics·Daisuke KobayashiIkumi Tamai
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Carl KyrklundPertti J Neuvonen
Jun 18, 2003·Clinical Pharmacology and Therapeutics·Yohei NishizatoYuichi Sugiyama
Aug 2, 2003·Pharmacogenetics·Deanna L KroetzUNKNOWN Pharmacogenetics of Membrane Transporters Investigators
Oct 11, 2003·Journal of Clinical Pharmacology·Katsutoshi OgawaKatsuji Oguchi
Jan 30, 2004·British Journal of Clinical Pharmacology·Carl KyrklundPertti J Neuvonen
Jan 30, 2004·Clinical Pharmacology and Therapeutics·Catia MarzoliniRichard B Kim

❮ Previous
Next ❯

Citations

Mar 10, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Jörg KönigMartin F Fromm
Mar 15, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Ernst Petzinger, Joachim Geyer
Jan 11, 2008·European Journal of Clinical Pharmacology·Jessica MwinyiThomas Gerloff
Jun 2, 2011·European Journal of Clinical Pharmacology·Eleni AklilluJohanna Weiss
Nov 9, 2007·Molecular Genetics and Genomics : MGG·Annick SeithelJörg König
Jul 22, 2008·Journal of Human Genetics·Suttasinee SuwannakulShun Higuchi
Feb 27, 2007·Cancer Metastasis Reviews·Ying Huang
Dec 21, 2006·Pharmaceutical Research·Kari T Kivistö, Mikko Niemi
Dec 2, 2009·Molecular Biotechnology·Tristan M SissungWilliam D Figg
Sep 29, 2012·Molecular Diagnosis & Therapy·Gaia Chiara Mannino, Giorgio Sesti
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Daniel I Chasman, Paul M Ridker
Apr 3, 2008·Nature Reviews. Drug Discovery·David A KatzLeonardo Sahelijo
Mar 22, 2006·The Pharmacogenomics Journal·L M MangraviteR M Krauss
Jul 19, 2006·Pharmacogenetics and Genomics·Mikko NiemiMichel Eichelbaum
Nov 17, 2006·Pharmacogenetics and Genomics·Marja K PasanenMikko Niemi
Nov 9, 2005·Current Opinion in Lipidology·Kouji KajinamiErnst J Schaefer
May 3, 2005·Pharmacogenetics and Genomics·Ching-Shan HuangKung-Sheng Tang
Jan 15, 2008·Pharmacogenetics and Genomics·Samuel FantaJanne T Backman
Oct 16, 2008·Pharmacogenetics and Genomics·Annikka KalliokoskiMikko Niemi
Dec 3, 2009·Pharmacogenetics and Genomics·Connie OshiroRuss Altman
Mar 14, 2007·Current Opinion in Lipidology·Gerd SchmitzPeter Ugocsai
Aug 13, 2005·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Magnus Ingelman-Sundberg, Cristina Rodriguez-Antona
Nov 2, 2007·Clinical and Experimental Pharmacology & Physiology·Wei ZhangHong-Hao Zhou
Apr 18, 2012·Journal of Gastroenterology and Hepatology·Akiko ShiotaniKen Haruma
Sep 22, 2007·Acta Pharmacologica Sinica·Lin-Yong XuZhen-Qiu Sun

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.